INAB
IN8BIO, INC.
$1.43
-0.69%
$14.1M
No data for this timeframe.
Vol
Market Cap$14.1M
Cap SizeNano Cap
Inst. Holders9 funds
Inst. Value$3.0M
Inst. Activity1 buys / 0 sells
Reddit Sentiment64° Warm
SEC Reports5
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001740279·Prev Close $1.44
Recent Activity
Jun 3, 2026
Press
IN8bio announced the publication of a review article in Nature Communications co-authored by its CSO, highlighting advan
Impact 3/10
Jun 3, 2026
fda
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell En
Jun 1, 2026
SEC
IN8bio entered into an at-the-market (ATM) equity offering agreement with JonesTrading to sell up to $2.8M of common sto
8-K — Impact 6/10
Jun 1, 2026
SEC
IN8bio filed a 424B5 prospectus supplement establishing an at-the-market (ATM) equity offering facility with JonesTradin
424B5 — Impact 6/10
May 27, 2026
Insider
FAIRBAIRN EMILY gifted 724,637 shares
Director
May 18, 2026
SEC
IN8bio filed Amendment No. 1 to its existing S-3 shelf registration, maintaining the $200M aggregate offering capacity f
S-3/A — Impact 7/10
May 9, 2026
Insider
Epperly Corinne was granted 22,000 shares
Director
May 9, 2026
Insider
Greenwood Luba was granted 22,000 shares
Director
Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$6.25 (Mar 2026)
Current $1.43
Low $4.00
Median $5.50
High $10.00
4 analysts
$4.00
$10.00
Analyst Ratings
2Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 13, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.37 ▲ +48.9% | $-0.61 — $-0.24 | 70% YoY | 3 |
| Next Q | $-0.38 ▲ +42.0% | $-0.69 — $-0.21 | 55% YoY | 3 |
| Current FY | $-1.24 ▲ +50.2% | $-2.10 — $-0.87 | 72% YoY | 4 |
| Next FY | $-1.06 ▲ +29.7% | $-1.51 — $-0.68 | 15% YoY | 4 |
Latest Reports
NEUTRAL
Press
3/10
IN8bio announced the publication of a review article in Nature Communications co-authored by its CSO, highlighting advan
Jun 3, 2026
BEARISH
8-K
6/10
IN8bio entered into an at-the-market (ATM) equity offering agreement with JonesTrading to sell up to $2.8M of common sto
Jun 1, 2026
BEARISH
424B5
6/10
IN8bio filed a 424B5 prospectus supplement establishing an at-the-market (ATM) equity offering facility with JonesTradin
Jun 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Alyeska Investment Group, L.P. | $1.4M | DOUBLED |
| FRANKLIN RESOURCES INC | $1.4M | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $132.0K | — |
| VANGUARD FIDUCIARY TRUST CO | $64.7K | — |
| CAPTRUST FINANCIAL ADVISORS | $49.3K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 27, 2026 | FAIRBAIRN EMILY | G | $0.00 |
| May 9, 2026 | Epperly Corinne | A | $0.00 |
| May 9, 2026 | Greenwood Luba | A | $0.00 |
| May 9, 2026 | Ho William | A | $0.00 |
| May 9, 2026 | Lamb Lawrence | A | $0.00 |
Reddit Sentiment
64°
Warm
Bearish
Neutral
Bullish
9 institutional holders with $3.0M total value (2,028,300 shares) as of 2026-Q1. Top holders: Alyeska, FRANKLIN, VANGUARD. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Alyeska Investment Group, L.P. | 944,319 | $1.4M | 46.5% | DOUBLED +1060.8% |
| 2 | FRANKLIN RESOURCES INC | 914,531 | $1.4M | 45.1% | DOUBLED +381.6% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 88,865 | $132.0K | 4.4% | — |
| 4 | VANGUARD FIDUCIARY TRUST CO | 43,570 | $64.7K | 2.2% | — |
| 5 | CAPTRUST FINANCIAL ADVISORS | 33,295 | $49.3K | 1.6% | ADD +82.0% |
| 6 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 2,785 | $4.1K | 0.1% | — |
| 7 | JONES FINANCIAL COMPANIES LLLP | 768 | $1.1K | 0.0% | — |
| 8 | BlackRock, Inc. | 84 | $124.00 | 0.0% | — |
| 9 | Rockefeller Capital Management L.P. | 83 | $123.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| CAPTRUST FINANCIAL ADVISORS | ADD | 18,295 | 33,295 | +82.0% | $49.3K | 2026-Q1 |
| Alyeska Investment Group, L.P. | DOUBLED | 82,484 | 957,484 | +1060.8% | $2.2M | 2025-Q4 |
| FRANKLIN RESOURCES INC | DOUBLED | 189,894 | 914,531 | +381.6% | $2.0M | 2025-Q4 |
| VANGUARD GROUP INC | TRIM | 59,418 | 28,348 | -52.3% | $66.3K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 49,453 | 28,214 | -42.9% | $66.0K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 24 | 36 | +50.0% | $78.00 | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 479 | 15 | -96.9% | $32.00 | 2025-Q3 |
| Alyeska Investment Group, L.P. | TRIM | 5,063,291 | 2,079,575 | -58.9% | $345.2K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 58,853 | 12,327 | -79.1% | $2.0K | 2025-Q1 |
| Alyeska Investment Group, L.P. | DOUBLED | 434,809 | 5,063,291 | +1064.5% | $1.3M | 2024-Q4 |
| UBS Group AG | DOUBLED | 26,270 | 58,853 | +124.0% | $15.1K | 2024-Q4 |
| Alyeska Investment Group, L.P. | TRIM | 641,008 | 434,809 | -32.2% | $117.4K | 2024-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 266 | 420 | +57.9% | $113.00 | 2024-Q3 |
7 unique insiders with 12 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 27, 2026 | FAIRBAIRN EMILY | Director | GIFT | 724,637 | — | — |
| May 9, 2026 | Epperly Corinne | Director | AWARD | 22,000 | — | — |
| May 9, 2026 | Greenwood Luba | Director | AWARD | 22,000 | — | — |
| May 9, 2026 | Ho William Tai-Wei | CEO | AWARD | 154,500 | — | — |
| May 9, 2026 | Lamb Lawrence | EVP and CSO | AWARD | 54,000 | — | — |
| May 9, 2026 | FAIRBAIRN EMILY | Director | AWARD | 22,000 | — | — |
| May 9, 2026 | McCall Patrick | CHIEF FINANCIAL OFFICER | AWARD | 56,250 | — | — |
| May 9, 2026 | Rochlin Kate | President and COO | AWARD | 60,000 | — | — |
| Feb 4, 2026 | Rochlin Kate | President and COO | AWARD | 80,000 | — | — |
| Feb 4, 2026 | McCall Patrick | CHIEF FINANCIAL OFFICER | AWARD | 75,000 | — | — |
| Feb 4, 2026 | Lamb Lawrence | EVP and CSO | AWARD | 72,000 | — | — |
| Feb 4, 2026 | Ho William Tai-Wei | CEO | AWARD | 206,000 | — | — |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 0 mixed, 2 neutral. Avg impact: 5.0/10.
BEARISH
8-K
6/10
IN8bio entered into an at-the-market (ATM) equity offering agreement with JonesTrading to sell up to
Jun 1, 2026
BEARISH
424B5
6/10
IN8bio filed a 424B5 prospectus supplement establishing an at-the-market (ATM) equity offering facil
Jun 1, 2026
BEARISH
S-3/A
7/10
IN8bio filed Amendment No. 1 to its existing S-3 shelf registration, maintaining the $200M aggregate
May 18, 2026
NEUTRAL
8-K
3/10
IN8bio reported Q1 2026 net loss of $5.1M ($0.26 per share), beating the -$0.59 consensus, driven by
May 7, 2026
NEUTRAL
DEFA14A
3/10
IN8BIO, INC. filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting of Stockholder
Mar 26, 2026
Historical analyst distribution (last covering-analyst action Mar 2026): 90% buy across 10 analysts — 2 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$6.25 mean target (Mar 2026)
$4.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $1.43 |
| Target Low | $4.00 |
| Target Mean | $6.25 |
| Target Median | $5.50 |
| Target High | $10.00 |
| # Analysts | 4 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.37 | $-0.61 | $-0.24 | 69.9% | +48.9% | — | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.38 | $-0.69 | $-0.21 | 55.3% | +42.0% | — | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-1.24 | $-2.10 | $-0.87 | 72.0% | +50.2% | 2↑ 1↓ | $0.0B | 0.0% | 4 |
| Next FY 2027-12-31 |
$-1.06 | $-1.51 | $-0.68 | 14.7% | +29.7% | 2↑ 1↓ | $0.0B | 0.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.373 | |
| 7d ago | $-0.373 | |
| 30d ago | $-0.730 | +0.357 |
| 60d ago | $-0.730 | +0.357 |
| 90d ago | $-0.255 | -0.118 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 13, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
64°
Warm
Bearish
Neutral
Bullish
3 mentions
2 bullish
0 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 6, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 6, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 26, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 3, 2026
fda
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
Jun 1, 2026
other
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
May 7, 2026
earnings
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 6, 2026
other
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
May 4, 2026
earnings_calendar
INAB Q1 2026 Earnings Scheduled — 2026-05-04
May 1, 2026
earnings_calendar
INAB Q1 2026 Earnings Scheduled — 2026-05-01
Apr 3, 2026
other
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mar 12, 2026
earnings
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results
Mar 2, 2026
earnings_calendar
INAB Q4 2025 Earnings After Market Close — 2026-03-02